Affordable Access

deepdyve-link
Publisher Website

A new version of targeted minicircle producer system for EBV-positive human nasopharyngeal carcinoma.

Authors
  • Zuo, Yufang
  • Liao, Sihai
  • Xu, Zumin
  • Xie, Jierong
  • Huang, Wenlin
  • Yu, Zhonghua
Type
Published Article
Journal
Oncology Reports
Publisher
Spandidos Publications
Publication Date
Dec 01, 2014
Volume
32
Issue
6
Pages
2564–2570
Identifiers
DOI: 10.3892/or.2014.3486
PMID: 25230680
Source
Medline
License
Unknown

Abstract

Targeted gene therapy needs to be implemented for future therapies to ensure efficient activity at the site of patient primary tumors or metastases without causing intolerable side-effects. One of the elements of gene therapy is vector, which includes viral and non-viral vector. In the present study, we constructed a novel non-viral targeted gene therapeutic system by using the new minicircle (MC) producing plasmid for Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (NPC). Molecular cloning technique was used to construct plasmids and electrophoretic analysis. Dual-luciferase reporter assay was used to evaluate the expression of luciferase. Fluorescence microscope was used to detect the expression of enhanced green fluorescence protein (EGFP). We constructed a new MC producing system pMC.BESPX-origin of plasmid replication (oriP), and demonstrated that this system could produce highly purified MC-oriP. Furthermore, our results showed that MC-oriP vector produced by the new system could mediate targeted luciferase gene expression in EBV-positive NPC cells. In addition, we verified that MC could mediate enhanced transgene expression compared with parent plasmid through EGFP transfection. The present study constructed a targeted expression vector pMC.BESPX-oriP which could carry diversified therapeutic genes for EBV-positive NPC and provides a new approach for MC-based therapies.

Report this publication

Statistics

Seen <100 times